TOBRAMYCIN OPHTHALMIC SOLUTION USP, 0.3 %

Manufacturer
FOSUN PHARMA USA INC | GLAND PHARMA LIMITED
Effective date
2021-09-16
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
legacy-cache
Hydrated at
2026-08-01 22:30:01

Label at a glance#

ProductTobramycin
Active ingredientTOBRAMYCIN
Label structure10 sections

Indications and uses

Tobramycin ophthalmic solution 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

Dosage and administration

In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Tobramycin ophthalmic solution USP, 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections.

Each mL of tobramycin ophthalmic solution USP, 0.3% contains: Active: tobramycin 0.3 % (3 mg). Preservative: benzalkonium chloride 0.01 % (0.1 mg). Inactives: boric acid, sodium sulfate decahydrate, sodium chloride, tyloxapol, sodium hydroxide and/or sulfuric acid (to adjust pH) and water for injection. Tobramycin ophthalmic solution USP, 0.3% has a pH range between 7.0 and 8.0 and an osmolality of 260-320 mOsm/kg.

Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens.
The chemical structure of tobramycin is:

tobramycin-spl-structure
tobramycin-spl-structure

 
Molecular Weight = 467.52
Molecular Formula: C 18H 37N 5O 9

Chemical name:
O-3-Amino-3-deoxy-α-D-glucopyranosyl-(1→4)-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl-(1→6)]-2-deoxy-L-streptamine.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION


In Vitro Data: In vitro studies

have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.
Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.
Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Tobramycin ophthalmic solution 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Tobramycin ophthalmic solution 0.3% is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients.

Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to tobramycin ophthalmic solution 0.3% occurs, discontinue use.

PRECAUTIONS

PRECAUTIONS SECTION

General: As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated. Cross-sensitivity to other aminoglycoside antibiotics may occur; if hypersensitivity develops with this product, discontinue use and institute appropriate therapy. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial ocular infection.


Information for Patients:
Do not touch dropper tip to any surface, as this may contaminate the solution.


Pregnancy: Reproduction studies in 3 types of animals at doses up to 33 times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Nursing Mothers: Because of the potential for adverse reactions in nursing infants from tobramycin ophthalmic solution, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use: Safety and effectiveness in pediatric patients below the age of 2 months has not been established.
Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.

GENERAL PRECAUTIONS

GENERAL PRECAUTIONS SECTION

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequent adverse reactions to tobramycin ophthalmic solution 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with tobramycin ophthalmic solution.


Postmarketing Experience: Additional adverse reactions identified from post-marketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme.

The following additional adverse reactions have been reported with systemic aminoglycosides: Neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, because of their potential effect on neuromuscular function.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

HOW SUPPLIED

HOW SUPPLIED SECTION

5 mL sterile solution supplied in opaque white low density polyethylene bottle which is closed with natural low density polyethylene nozzle and then with Tan colored high density polyethylene cap as follows:

5 mL containing tobramycin 0.3% (3 mg/mL)…. NDC 72266-196-01



Storage: Store at 2°C to 25°C (36°F to 77°F).

After opening, Tobramycin Ophthalmic Solution, USP 0.3% can be used until the expiration date on the bottle.

Distributed by:

Fosun Pharma USA Inc.

Princeton, NJ 08540

Made in India.

Issued: 07/2021

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Bottle Label:

NDC 72266-196-01

Tobramycin Ophthalmic solution, USP 0.3%

Sterile 5 mL Rx Only

tobramycin-spl-container-labeltobramycin-spl-container-label

Carton Label:

NDC 72266-196-01

Tobramycin Ophthalmic solution, USP 0.3%

5 mL Sterile Rx Only

tobramycin-spl-carton-labeltobramycin-spl-carton-label

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
72266-196-01ML - Milliliter72266-196b9aade57-545e-4a16-b219-5001786583a912022-01-06

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
72266-19672266-196-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A212628-001TOBRAMYCINTOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A212628-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-0984e616aacf4f…
2026-08-18 06:07:402026-07A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-0931067a03dcf5…
2025-08-23 18:47 UTC2025-08A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-096a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-0903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-092680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-095bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-0979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-091e350fbaab3a…
2024-05-31 18:47 UTC2024-05A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-098072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-095c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-095d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-094b0b4de00fa7…
2022-03-09 01:35 UTC2022-03A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-0987673890dc5c…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-096a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-091c564ffb4f44…
2023-12-20 04:57 UTC2023-12A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-099b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-093f0d92c62455…
2023-05-13 08:27 UTC2023-05A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09053a50430f4f…
2023-01-26 05:58 UTC2023-01A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-093bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-093a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A212628-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A212628-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A212628-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A212628-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A212628-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A212628-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A212628-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A212628-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A212628-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A212628-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A212628-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A212628-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A212628-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A212628-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A212628-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A212628-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A212628-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A212628-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A212628-001AT14b0b4de00fa7…
2022-03-09 01:35 UTC2022-03A212628-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A212628-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A212628-001AT187673890dc5c…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A212628-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A212628-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A212628-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A212628-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A212628-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A212628-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A212628-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A212628-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A212628-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A212628-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A212628-001AT1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A212628-001AT1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A212628-001AT1cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A212628-001AT1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
17cd6c73-661c-3977-e063-6294a90aa493cc22973b-642e-ba6e-e053-2a95a90ad73f2024-05-06Warnings, Adverse reactionsExact identifier
spl set id: cc22973b-642e-ba6e-e053-2a95a90ad73f

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.